Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HW252001 Tablets After Single and Multiple Dosing in Healthy Subjects

NCT07493031 is registered in ClinicalTrials.gov with Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. as lead sponsor.

NCT NCT07493031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07493031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HW252001 Tablets After Single and Multiple Dosing in Healthy Subjects
Lead sponsor
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
December 11, 2026
Enrollment
98 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ipf